Moderate

Juvenile idiopathic arthritis

rheumatology · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic arthritis beginning before age 16 and persisting at least 6 weeks, with no other identified cause. Several subtypes exist; early diagnosis and treatment prevent joint damage, and uveitis screening protects sight.

Red flags

  • Fever, weight loss, bone pain or cytopenias (exclude leukaemia before steroids)
  • Features of macrophage activation syndrome in systemic JIA (high fever, cytopenias, high ferritin)
  • Acutely hot, immobile joint with systemic upset (septic arthritis)
  • Visual symptoms or detected uveitis

Assessment

Differential diagnosis

  • Reactive/post-infectious arthritis
  • Septic arthritis or osteomyelitis
  • Lyme arthritis
  • Leukaemia or bone tumour
  • Systemic lupus or other connective tissue disease
  • Henoch-Schonlein purpura / vasculitis
  • Haemarthrosis or orthopaedic/mechanical cause

Investigations

  • Clinical diagnosis of persistent arthritis after excluding other causes
  • FBC, ESR/CRP, blood film (exclude malignancy)
  • ANA (uveitis risk), rheumatoid factor, HLA-B27 as relevant to subtype
  • Joint ultrasound/MRI to confirm synovitis
  • Exclude infection (joint aspiration if septic arthritis possible)
  • Slit-lamp ophthalmology screening for asymptomatic uveitis

Management

  • Confirm persistent arthritis (>=6 weeks) and determine the number of joints and systemic features
  • Exclude mimics, particularly infection and malignancy, before immunosuppression
  • Arrange prompt slit-lamp examination to detect silent uveitis
  • Refer to paediatric rheumatology for diagnosis and subtype classification
  • Start NSAIDs and intra-articular corticosteroid injections for symptom control
  • Introduce methotrexate early for persistent/polyarticular disease
  • Escalate to biologic therapy for inadequate response or systemic disease
  • Provide physiotherapy, occupational therapy and multidisciplinary support
  • Maintain regular ophthalmology surveillance and monitor for medication toxicity

Drugs & doses

Naproxen ~10 mg/kg/day PO in divided doses (symptom control)
Intra-articular triamcinolone injections for oligoarticular disease (specialist)
Methotrexate 10-15 mg/m2 once weekly PO/SC with folic acid
Biologics (e.g. etanercept, adalimumab, tocilizumab) for refractory/systemic disease (specialist)

Disposition

Paediatric rheumatology management with ophthalmology surveillance; admit for systemic disease, suspected MAS, or septic arthritis exclusion.

Complications & pitfalls

  • Joint damage, contractures and growth disturbance
  • Chronic anterior uveitis with visual loss
  • Macrophage activation syndrome (systemic JIA)
  • Medication toxicity and growth/psychosocial effects

Exam pearls

  • Always exclude leukaemia with blood film/counts before giving steroids to a child with joint pain
  • ANA-positive young girls with oligoarthritis have the highest uveitis risk and need frequent screening
  • Early methotrexate changes the disease course and limits damage
  • Uveitis is often asymptomatic; regular slit-lamp screening is essential

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.